Shares of Amarin (AMRN -20.5%) are getting hammered this morning on the back of yesterday's...

Shares of Amarin (AMRN -20.5%) are getting hammered this morning on the back of yesterday's announcement that it was raising funds and will begin hiring a sales force to independently launch Vascepa. The news disappointed investors who had hoped the biotech would have a partner by now. The company has already undertaken extensive preparations to launch the drug, but had held off on the costly move of hiring its own sales staff.

From other sites
Comments (4)
  • ralphey
    , contributor
    Comments (382) | Send Message
    BUY now !!!
    7 Dec 2012, 11:29 AM Reply Like
  • rdimick
    , contributor
    Comment (1) | Send Message
    I bought more!!!!
    7 Dec 2012, 11:45 AM Reply Like
  • Belle888
    , contributor
    Comments (2) | Send Message
    This is a great opportunity to buy low and sell high. Please see this as a great opportunity to purchase this stock at these low levels,,,with tremendous potential upside. Don't be out of this stock on its natural upswing from these lows and from any potential good news concerning partnership/buyout.
    7 Dec 2012, 03:12 PM Reply Like
  • yourmama6799
    , contributor
    Comments (488) | Send Message
    Why is it that many people pumping this stock only have one or two comments, perhaps they are telling us to buy while they short?
    7 Dec 2012, 09:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs